Our Western Blot analysis revealed that PAM treatment downregulated the expression levels of RAS, p-ERK, and Cyclin D1, inhibited the EMT process, as well as the expression of extracellular matrix enzymes MMP-2 and MMP-9, indicating that PAM treatment can affect NSCLC cells function through these pathways (Figure 8). The gene discussed is CCND1; the disease is non-small cell lung carcinoma.